Understanding TSC management guidelines, mTOR inhibitors and TS Cure - Dr David Mowat
Understanding TSC management guidelines, mTOR inhibitors and TS Cure - Dr David Mowat
|
Loading...
Lütfen bekleyiniz...
Type
Size

İlgili Videolar

Understanding TSC management guidelines, mTOR inhibitors and TS Cure - Dr David Mowat

Understanding TSC management guidelines, mTOR inhibitors and TS Cure - Dr David Mowat

|
Managing the signs of TSC on the skin - Dr Anne Halbert

Managing the signs of TSC on the skin - Dr Anne Halbert

|
Emerging Emerging treatments for epilepsy in TSC: Medicinal Cannabis and mTOR inhibitor medicines

Emerging Emerging treatments for epilepsy in TSC: Medicinal Cannabis and mTOR inhibitor medicines

|
Einstein Tuberous Sclerosis Conference, Dr. Elizabeth Thiele (6 of 8)

Einstein Tuberous Sclerosis Conference, Dr. Elizabeth Thiele (6 of 8)

|
How the Consensus Guidelines Improve Treatment and Care for Individuals with TSC

How the Consensus Guidelines Improve Treatment and Care for Individuals with TSC

|
Global Status of TSC and Consensus Guidelines for Diagnosis, Surveillance, and Treatment

Global Status of TSC and Consensus Guidelines for Diagnosis, Surveillance, and Treatment

|
LIFE STAGES: Refractory Epilepsy in Adults with TSC

LIFE STAGES: Refractory Epilepsy in Adults with TSC

|
01 Surveillance Protocols for TSC: Why is it important?

01 Surveillance Protocols for TSC: Why is it important?

|
TSA Research: Forthcoming trial of topical sirolimus for facial angiofibromas in TSC

TSA Research: Forthcoming trial of topical sirolimus for facial angiofibromas in TSC

|
Tuberous Sclerosis Complex and the Kidneys

Tuberous Sclerosis Complex and the Kidneys

|
Achievements in Tuberous Sclerosis Research

Achievements in Tuberous Sclerosis Research

|
Targeting Critical Oncogenic Pathways in Cancer

Targeting Critical Oncogenic Pathways in Cancer

|
3. Treatment of TAND

3. Treatment of TAND

|
New Clinical Directions with ABI‐009, a Targeted Nanoparticle mTOR Inhibitor

New Clinical Directions with ABI‐009, a Targeted Nanoparticle mTOR Inhibitor

|
Managing signs of TSC and LAM in the kidneys- A/Prof Nikky Isbel

Managing signs of TSC and LAM in the kidneys- A/Prof Nikky Isbel

|
Angiomyolipomas: Current evidence and its effect on management

Angiomyolipomas: Current evidence and its effect on management

|
LAM Basic Facts - Professor Simon Johnson

LAM Basic Facts - Professor Simon Johnson

|
Dermatologic Manifestations of TSC

Dermatologic Manifestations of TSC

|
Surgical Approaches and Assessments for Epilepsy and SEGA

Surgical Approaches and Assessments for Epilepsy and SEGA

|
2. TAND Checklist

2. TAND Checklist

|
Copyright. All rights reserved © 2025
Rosebank, Johannesburg, South Africa